AACR24: Having entered the clinic last night, Nested's CEO discusses the preclinical profile of a brain-penetrant, pan-RAF/MEK molecular glue

blonca9
Apr 9, 2024
1 min read

Disclosing to BiotechTV that the program has dosed its first patient last night, Darrin Miles describes how this molecular glue therapy has been designed to bind to MEK and all isoforms of MEK and RAF in combination.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

AACR24: Having entered the clinic last night, Nested's CEO discusses the preclinical profile of a brain-penetrant, pan-RAF/MEK molecular glue

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight